| Filed On | Filing |
|---|---|
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of uveal melanoma in both primary and metastatic disease, irrespective of HLA-A*02:01 allel... |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology review program (RTOR) with completion... |
| 23 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
On June 16, 2026, IDEAYA Biosciences, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described in mor... |
| 10 Jun 2026 |
8-K: Other Events
Pre-Funded Warrants to Purchase 5,555,576 Shares of Common Stock |
| 03 Jun 2026 |
8-K: Other Events
On June 3, 2026, IDEAYA Biosciences, Inc. (the “Company”) announced it has entered into a clinical collaboration with F. Hoffmann-La Roche Ltd (“Roche”) to evaluate the efficacy and safety of IDE892, its investigational, potential best-i... |
| 01 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Darovasertib Plus Crizotinib vs Investigator’s Choice as First-Line Treatment for Patients with HLA-A2 Negative Metastatic Uveal Melanoma: Primary Results from the OptimUM-02 Trial Marlana Orloff,1 Egle Ramelyte,2 Marcus O. Butler,3 Piot... |
| 05 May 2026 |
8-K: Other Events
Re: Registration Statement No. 333-295560; Up to $156,552,996.81 Shares of Common Stock, par value $0.0001 per share |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint; complete data will be provided in a late-breaking oral presentation at ASCO |
| 13 Apr 2026 |
8-K: Other Events
On April 13, 2026, IDEAYA Biosciences, Inc. (the “Company”) and Servier, an independent international pharmaceutical group governed by a foundation, announced clinical data from the Company’s Phase 2/3 registrational trial, OptimUM-02, e... |
| 09 Apr 2026 |
8-K: Other Events
On April 8, 2026, IDEAYA Biosciences, Inc. (the “Company”) entered into a clinical collaboration agreement with AstraZeneca plc (“AstraZeneca”) to evaluate the efficacy and safety of IDE849, the Company’s investigational, potential first... |
| 17 Feb 2026 |
8-K: Results of Operations and Financial Condition
130 required PFS events confirmed by BICR in the Phase 2/3 OptimUM-02 trial of darovasertib and crizotinib combination in 1L HLA*A2-negative metastatic uveal melanoma (mUM); topline results expected by approximately the last week of March |
| 12 Jan 2026 |
8-K: Other Events
On January 11, 2026, IDEAYA Biosciences, Inc. (the “Company”) provided a business update including an overview of key corporate objectives for 2026. The company will review these updates during its presentation at the 44th Annual J.P. Mo... |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
Improving Lives Through Transformative Precision Medicines JPM 2026 | 44th Annual Healthcare Conference January 2026 Exhibit 99.1 |
| 12 Dec 2025 |
8-K: Termination of a Material Definitive Agreement
On December 9, 2025, GlaxoSmithKline Intellectual Property (No. 4) Limited (“GSK”) delivered written notice to IDEAYA Biosciences, Inc. (the “Company”) of its election to terminate the Collaboration, Option and License Agreement, dated J... |
| 05 Dec 2025 |
8-K: Other Events
On December 4, 2025, GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) (“GSK”) communicated to IDEAYA Biosciences, Inc. (the “Company”) its election to terminate the Collaboration, Option and License Agreement, dated June 15, 2020 (as amende... |
| 04 Nov 2025 |
8-K: Results of Operations and Financial Condition
Phase 2/3 trial (OptimUM-02) of the darovasertib/crizotinib combination in 1L HLA*A2-negative metastatic uveal melanoma (mUM) to report median PFS data by year-end 2025 to 1Q 2026; on track to complete enrollment by year-end |
| 20 Oct 2025 |
8-K: Other Events
Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma |
| 08 Sep 2025 |
8-K: Other Events
Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer |
| 02 Sep 2025 |
8-K: Entry into a Material Definitive Agreement
On August 29, 2025, IDEAYA Biosciences, Inc. (the “Company”) entered into a License Agreement (the “Agreement”) with Les Laboratoires Servier (“Servier”) pursuant to which the Company granted to Servier an exclusive license under certain... |
| 05 Aug 2025 |
8-K: Results of Operations and Financial Condition
Phase 2/3 trial of the darovasertib and crizotinib combination in 1L HLA-A2-negative metastatic uveal melanoma (MUM) on track to report median PFS data by year-end 2025; potential to enable a U.S. accelerated approval filing |
Loading...